Ob/Gyn

Benefits include improved hematocrit levels and lower rates of anemia throughout pregnancy and immediately postpartum.

Race disparities reported in 10 of 20 studies; all showed that Black women had lower use, prescribing, counseling for MHT.

Ibrexafungerp is an oral triterpenoid antifungal.

High treatment success rate observed for vaginal and cesarean births across all bleeding causes.

Metronidazole is a nitroimidazole antimicrobial.

Associations seen for all individual substances; association strongest for amphetamine/methamphetamine.

FDA advisers are meeting this week to hammer out the possibilities and parameters for experiments with artificial wombs for premature human babies.

Screening with blood pressure measurements has substantial net benefits and is recommended throughout pregnancy.

New report shows that many women might need to get Opill at the pharmacy counter, and not off store shelves, for their insurance company to cover it.

NSAID use positively linked to VTE, with extra VTE events in those with concomitant high-, medium-risk contraception use.

Authors say mean treatment effect for hot flash frequency may only be 21%.

Risk for stroke hospitalization within 12 months of delivery higher for those who received infertility treatment vs spontaneous conception.

Selective serotonin reuptake inhibitor treatment tied to lower risk for maternal mental health problems and child externalizing behaviors across early childhood.

Adherence to AHA dietary pattern inversely linked to pregnancy loss during infertility treatment with IVF, intrauterine insemination.

The investigational therapy is designed to decrease the production of soluble fms-like tyrosine kinase-1 (sFLT1) mRNA isoforms in the placenta.

Abyrsvo is the first vaccine approved for pregnant individuals to prevent RSV disease in infants.

Vaginal estrogen does appear beneficial for reducing atrophy-related symptoms and for improving vaginal tissue quality.

Levonorgestrel plus piroxicam prevented 94.7% of expected pregnancies compared with 63.4% with levonorgestrel plus placebo.

Health care providers have said they will switch to using only misoprostol, which is somewhat less effective.